# IPL and MGX Versus MGX Alone in the Treatment of Dry Eye Disease Secondary to MGD

> **NCT03265652** · NA · COMPLETED · sponsor: **Lumenis Be Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Dry Eye
- Meibomian Gland Dysfunction

## Interventions

- **DEVICE:** Intense Pulsed Light (IPL) therapy
- **DEVICE:** Sham therapy

## Key facts

- **NCT ID:** NCT03265652
- **Lead sponsor:** Lumenis Be Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-15
- **Primary completion:** 2019-04-18
- **Final completion:** 2019-04-18
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03265652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03265652, "IPL and MGX Versus MGX Alone in the Treatment of Dry Eye Disease Secondary to MGD". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03265652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*